BLTE — Belite Bio Income Statement
0.000.00%
Last trade - 00:00
HealthcareMid Cap
- $2.34bn
- $2.25bn
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 20-F | 20-F |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Total Operating Expenses | 5.74 | 9.8 | 12.8 | 31.7 |
Operating Profit | -5.74 | -9.8 | -12.8 | -31.7 |
Total Net Non Operating Interest Income / Expense | ||||
Net Income Before Taxes | -5.75 | -9.67 | -12.6 | -31.6 |
Provision for Income Taxes | ||||
Net Income After Taxes | -5.75 | -9.67 | -12.6 | -31.6 |
Net Income Before Extraordinary Items | ||||
Net Income | -5.75 | -9.67 | -12.6 | -31.6 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -5.75 | -9.67 | -12.6 | -31.6 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -0.239 | -0.401 | -0.633 | -1.19 |